SCANDONEST PLAIN Drug Patent Profile
✉ Email this page to a colleague
When do Scandonest Plain patents expire, and what generic alternatives are available?
Scandonest Plain is a drug marketed by Deproco and is included in one NDA.
The generic ingredient in SCANDONEST PLAIN is mepivacaine hydrochloride. There are six drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the mepivacaine hydrochloride profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for SCANDONEST PLAIN?
- What are the global sales for SCANDONEST PLAIN?
- What is Average Wholesale Price for SCANDONEST PLAIN?
Summary for SCANDONEST PLAIN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 9 |
| Raw Ingredient (Bulk) Api Vendors: | 113 |
| Clinical Trials: | 2 |
| Patent Applications: | 1,043 |
| DailyMed Link: | SCANDONEST PLAIN at DailyMed |
Recent Clinical Trials for SCANDONEST PLAIN
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Cairo University | N/A |
| Afshan Amjad Ali | Phase 2 |
Pharmacology for SCANDONEST PLAIN
| Drug Class | Amide Local Anesthetic |
| Physiological Effect | Local Anesthesia |
US Patents and Regulatory Information for SCANDONEST PLAIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Deproco | SCANDONEST PLAIN | mepivacaine hydrochloride | INJECTABLE;INJECTION | 088387-001 | Oct 10, 1984 | RX | No | Yes | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
